Fairmount Funds Management as of Sept. 30, 2022
Portfolio Holdings for Fairmount Funds Management
Fairmount Funds Management holds 27 positions in its portfolio as reported in the September 2022 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Axsome Therapeutics (AXSM) | 14.9 | $85M | 1.9M | 44.62 | |
| Cogent Biosciences (COGT) | 7.2 | $41M | 2.8M | 14.92 | |
| Nuvalent Inc-a (NUVL) | 7.1 | $40M | 2.1M | 19.44 | |
| BioCryst Pharmaceuticals (BCRX) | 5.6 | $32M | 2.5M | 12.60 | |
| Biohaven Pharmaceutical Holding | 5.4 | $31M | 205k | 151.17 | |
| Neurocrine Biosciences (NBIX) | 5.3 | $30M | 283k | 106.21 | |
| Insmed Com Par $.01 (INSM) | 5.1 | $29M | 1.3M | 21.54 | |
| Miragen Therapeutics (VRDN) | 4.9 | $28M | 1.4M | 20.51 | |
| Verona Pharma Sponsored Ads (VRNA) | 4.8 | $27M | 2.7M | 10.22 | |
| Axsome Therapeutics Call Option | 4.7 | $27M | 600k | 44.62 | |
| Argenx Se Sponsored Adr (ARGX) | 4.6 | $26M | 74k | 353.05 | |
| Enanta Pharmaceuticals (ENTA) | 4.3 | $24M | 469k | 51.87 | |
| Point Biopharma Global | 3.9 | $22M | 2.8M | 7.73 | |
| Annexon (ANNX) | 3.6 | $21M | 3.4M | 6.18 | |
| Dbv Technologies Sa Sponsored Adr | 2.2 | $13M | 7.1M | 1.77 | |
| Tyra Biosciences (TYRA) | 2.2 | $13M | 1.4M | 8.79 | |
| ACADIA Pharmaceuticals (ACAD) | 2.2 | $12M | 752k | 16.36 | |
| Terns Pharmaceuticals (TERN) | 2.1 | $12M | 2.1M | 5.89 | |
| Beigene Sponsored Adr (BGNE) | 2.0 | $12M | 86k | 134.81 | |
| Keros Therapeutics (KROS) | 1.8 | $10M | 273k | 37.62 | |
| Trevi Therapeutics (TRVI) | 1.5 | $8.8M | 5.7M | 1.54 | |
| Astria Therapeutics (ATXS) | 1.4 | $8.2M | 912k | 9.04 | |
| Amarin Corp Spons Adr New (AMRN) | 1.1 | $6.1M | 5.6M | 1.09 | |
| Iovance Biotherapeutics (IOVA) | 0.7 | $3.7M | 390k | 9.58 | |
| Olema Pharmaceuticals (OLMA) | 0.6 | $3.4M | 1.2M | 2.76 | |
| Instil Bio | 0.6 | $3.3M | 674k | 4.84 | |
| Allakos (ALLK) | 0.2 | $901k | 147k | 6.12 |
